Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 22, 2002

View Archived Issues

Vertex updates latest R&D progress

AlphaRx to sublicense cancer therapeutic from Select Therapeutics

Hypermethylated genes targeted by decitabine in MDS

CC-5013 effective and well tolerated in multiple myeloma

New data on the antitumor efficacy of ABX-EGF reported at Society for Biological Therapy meeting

IGN-311 reported safe in rhesus monkeys

First E.U. launch of frovatriptan in Germany

Guilford withdraws European regulatory submission for expanded use of Gliadel Wafer

Hemolink cleared for evaluation in phase II orthopedic surgery trial

Novel adenosine A3 agonists for preventing myocardial ischemic damage

Lundbeck enters agreement with Janssen-Cilag for Cipramil and Lexapro in China

Cannabinoid CB2 receptor modulators under study at Shionogi

GSK presents novel PcrA helicase inhibitors as potential antibacterial agents

Ono reports prostanoid EP1 antagonists for urinary incontinence, pain, etc.

Series of PDE4 inhibitors in early development at Glenmark

Avanir presents novel compounds with IgE-modulatory and antiproliferative activity

Novel antibacterial agents isolated from Bacillus species

Sumitomo scientists identify new compounds for arthritis and bone diseases

Kaleidos enters collaboration with NIH to evaluate TGF-alpha for treatment of AIDS

DTI-0009 useful for controlling atrial fibrillation without effects on blood pressure

Small-molecule inhibitors of HER signaling characterized at EORTC-NCI-AACR meeting

Lycobetaine derivatives with improved antitumor activity

DNA-targeted anticancer agent DRH-417 undergoes preclinical testing

Phase I/II clinical findings for MTC-DOX reported at EORTC-NCI-AACR symposium

INS-37217 enters phase III trials for perennial allergic rhinitis

Phase I trial of ETX-100 in hereditary pulmonary disorder initiated

Lundbeck to acquire U.S.-based Synaptic

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...